A Phase 1 interventional study of Chlamydia mRNA Vaccine and Placebo in Chlamydia Trachomatis Immunization, sponsored by Sanofi. Recruiting at 7 sites in Australia. Open to participants aged 18 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Sanofi · Phase 1, Interventional, and Prevention
Sentinel Cohort C Group 7: Chlamydia trachomatis Seropositive · Sentinel Cohort A, B and C Group 8: Chlamydia trachomatis Seropositive · Main Cohort Group 9: Chlamydia trachomatis Seronegative · Main Cohort Group 10: Chlamydia trachomatis Seronegative · Main Cohort Group 11: Chlamydia trachomatis Seronegative · Main Cohort Group 12: Chlamydia trachomatis Seronegative · Main Cohort Group 13: Chlamydia trachomatis Seropositive · Main Cohort Group 14: Chlamydia trachomatis Seropositive · Main Cohort Group 15: Chlamydia trachomatis Seropositive · Main Cohort Group 16: Chlamydia trachomatis Seropositive
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety of two doses (Dose 1 and Dose 2) of Chlamydia mRNA Vaccine candidate in adult participants aged 18 to 29 years (Chlamydia trachomatis seronegative) or 18 to 44 years (Chlamydia trachomatis seropositive). There will also be an assessment to potentially obtain an early immunogenicity signal of the Chlamydia mRNA vaccine candidate.
This study will consist of 2 Cohorts assessing the safety of the two different doses: Cohort A (Dose 1 or placebo) and Cohort B (Dose 2 or placebo).
All participants will be followed up to 12 months after the last study intervention administration. Thus, the expected duration of the participant's involvement will be 18 months.
134 studies on the registry are indexed under Chlamydia Infections; 23 are open to participants now.
This study's planned enrollment of 80 is below the median of 600 across 94 interventional studies indexed under Chlamydia Infections.
Browse Chlamydia Infections studies →Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 2, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:
OR
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive three dose 1 injections of Chlamydia mRNA Vaccine
Biological: Chlamydia mRNA Vaccine
Participants will receive three dose 2 injections of Chlamydia mRNA Vaccine
Biological: Chlamydia mRNA Vaccine
Participants will receive three injections of Placebo
Other: Placebo
Participants will receive three dose 1 injections of Chlamydia mRNA Vaccine
Biological: Chlamydia mRNA Vaccine
Participants will receive three dose 2 injections of Chlamydia mRNA Vaccine
Biological: Chlamydia mRNA Vaccine
Participants will receive three injections of Placebo
Other: Placebo
Pharmaceutical Form: Suspension for injection Route of Administration: Intramuscular injection
Pharmaceutical Form: Solution for injection Route of Administration: Intramuscular injection
Presence of immediate unsolicited systemic adverse events (AEs)
Number of participants with immediate unsolicited systemic adverse events (AEs) reported in the 30 minutes after each vaccine injection.
Time frame: Within 30 minutes after each vaccine injection
Presence of solicited injection site and systemic reactions
Number of participants with solicited injection site and systemic reactions occurring up to 8 days after each vaccine injection.
Time frame: Up to 8 days, including the day of each vaccine injection
Presence of unsolicited AEs
Participants with unsolicited AEs reported up to 28 days after each vaccine injection.
Time frame: Up to 28 days after each vaccine injection.
Presence of medically attended adverse events (MAAEs)
Number of participants with MAAEs reported after each vaccine injection and up to 6 months after last vaccine injection.
Time frame: Up to 6 months after last vaccine injection
Presence of all serious AEs (SAEs) and all adverse events of special interest (AESIs)
Number of participants with SAEs and all AESIs reported after each vaccine injection and up to 12 months after last vaccine injection
Time frame: Up to 12 months after last vaccine injections
Presence of related SAEs, and fatal SAEs
Number of participants with related SAEs, and fatal SAEs throughout the study
Time frame: Throughout the study, appriximatley 18 months
Presence of out-of-range biological test results (Sentinel Cohort and Safety Subset of Main Cohort)
Number of participants with out-of-range biological test results up to 8 days after each vaccine injection
Time frame: Up to 8 days, including the day of each vaccine injection
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Started Mar 2025 (actual). Primary completion is estimated for Nov 2027, 31 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Jan 2028 → Nov 2027 and completion Jan 2028 → Nov 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Sentinel Cohort C Group 7: Chlamydia trachomatis Seropositive · Sentinel Cohort A, B and C Group 8: Chlamydia trachomatis Seropositive · Main Cohort Group 9: Chlamydia trachomatis Seronegative · Main Cohort Group 10: Chlamydia trachomatis Seronegative · Main Cohort Group 11: Chlamydia trachomatis Seronegative · Main Cohort Group 12: Chlamydia trachomatis Seronegative · Main Cohort Group 13: Chlamydia trachomatis Seropositive · Main Cohort Group 14: Chlamydia trachomatis Seropositive · Main Cohort Group 15: Chlamydia trachomatis Seropositive · Main Cohort Group 16: Chlamydia trachomatis Seropositive
Sentinel Cohort C Group 7: Chlamydia trachomatis Seropositive · Sentinel Cohort A, B and C Group 8: Chlamydia trachomatis Seropositive · Main Cohort Group 9: Chlamydia trachomatis Seronegative · Main Cohort Group 10: Chlamydia trachomatis Seronegative · Main Cohort Group 11: Chlamydia trachomatis Seronegative · Main Cohort Group 12: Chlamydia trachomatis Seronegative · Main Cohort Group 13: Chlamydia trachomatis Seropositive · Main Cohort Group 14: Chlamydia trachomatis Seropositive · Main Cohort Group 15: Chlamydia trachomatis Seropositive · Main Cohort Group 16: Chlamydia trachomatis Seropositive
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.